• Emergency
    • Apollo Lifeline

    Emergency

      Home Blog Apollo Cancer Centre’s Experts Perform, India’s First Robotic CRS with HIPEC for Peritoneal Surface Cancer

      Apollo Cancer Centre’s Experts Perform, India’s First Robotic CRS with HIPEC for Peritoneal Surface Cancer

      Cardiology Image 1 Verified By May 1, 2024

      140
      Apollo Cancer Centre’s Experts Perform, India’s First Robotic CRS with HIPEC for Peritoneal Surface Cancer

      In a remarkable medical milestone, experts at Apollo Cancer Centres have successfully
      performed India’s first Robotic Cytoreductive Surgery (CRS) with Hyperthermic
      Intraperitoneal Chemotherapy
      (HIPEC) for peritoneal surface cancer. This innovative
      approach marks a significant advancement in the treatment of peritoneal malignancies,
      offering patients a minimally invasive and effective treatment option.

      What is Robotic Cytoreductive Surgery (Robotic CRS) and how it is different and
      preferred as compare to Cytoreductive Surgery

      Cytoreductive Surgery (CRS) is a surgical procedure aimed at removing visible tumors and
      affected tissues from the abdominal cavity in patients with peritoneal surface cancer. This
      surgery is traditionally performed using open techniques, which involve a large incision and
      manual manipulation of tissues by the surgeon.

      Robotic Cytoreductive Surgery (Robotic CRS) is a minimally invasive approach that uses
      robotic-assisted technology to perform the surgery. Instead of a large incision, several small
      incisions are made in the abdomen, through which robotic arms equipped with surgical
      instruments are inserted. The surgeon controls these instruments from a console, allowing
      for precise and controlled movements.
      Robotic CRS offers several advantages over traditional open surgery, providing patients with
      a potentially safer, more effective, and less invasive treatment option.

      Understanding Peritoneal Surface Cancer and Robotic CRS with HIPEC

      Peritoneal malignancies are cancers that have spread to the peritoneum, the lining of the
      abdomen. Robotic CRS with HIPEC is a specialized procedure that combines robotic-
      assisted surgery with heated chemotherapy to target cancerous tissues in the abdominal
      cavity.

      Procedure Overview

      1. Robotic Surgical Access: Surgeons make small incisions in the abdomen to create access for the robotic instruments and camera.
      2. Exploration and Tumor Assessment: The robotic camera is used to explore the abdominal cavity and assess the distribution, size, and extent of tumors.
      3. Cytoreductive Surgery (CRS): Surgeons identify and remove all visible tumors and affected tissues, aiming for optimal cytoreduction.
      4. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Heated chemotherapy drugs are circulated throughout the abdomen to kill remaining cancer cells after surgery.
      5. Robotic CRS

      6. Surgical Site Closure & Recovery: Port sites and incisions are closed, and the
        patient is monitored closely during recovery.

      Advantages of Robotic CRS with HIPEC

      • Equivalent Survival Rates: Rates: Studies have shown that survival rates with RCRS with
        HIPEC is equivalent to open surgery
      • Reduced Complications: The minimally invasive nature of robotic surgery results in
        fewer post-operative complications and less pain.
      • Faster Recovery: Patients experience shorter hospital stays and faster recovery
        times compared to traditional open surgery.
      • Enhanced Surgical Precision: Robotic technology allows for meticulous dissection
        and tissue preservation, minimizing trauma and blood loss.
      • Improved Quality of Life: Patients benefit from a faster return of bowel function,
        decreased wound infection rates, and less postoperative adhesions.
      • Improved Cosmesis: Smaller incisions and less tissue damage can result in
        improved cosmetic outcomes for patients, with smaller scars and a more
        aesthetically pleasing appearance after surgery.
      • Reduced Pain and Discomfort: The minimally invasive nature of robotic CRS can
        result in reduced post-operative pain and discomfort for patients compared to
        traditional open surgery.

      Patient Story:

      • Age and Presentation: A 40-year-old female patient presented with bilateral ovarian
        masses.
      • Diagnosis: Diagnosed as high-grade pseudomyxoma peritonei (PMP) of the
        appendix.
      • Treatment: Underwent robotic CRS with right hemicolectomy and HIPEC. Achieved
        complete cytoreduction (CC-0) of the mucinous implants.
      • Outcome: Had a smooth postoperative course and was discharged on postoperative
        day 6 and is back to normal life again
        • India’s first successful Robotic CRS with HIPEC, led by Dr. Ajit Pai and his pioneering team,
          represents a significant advancement in surgical oncology. This groundbreaking procedure
          offers new hope to patients with peritoneal surface malignancies, providing them with a
          minimally invasive and effective treatment option.

          Additional read –

          What is Robotic Onco Surgery
          All about HIPEC treatment

          Know our expert – Dr Ajit Pai

      Cardiology Image 1

      Related Articles

      More Articles

      Most Popular Articles

      More Articles
      © Copyright 2025. Apollo Hospitals Group. All Rights Reserved.
      Book ProHealth Book Appointment
      Request A Call Back X